Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C. Murawski N, et al. Among authors: hanel m. Ann Oncol. 2014 Sep;25(9):1800-1806. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13. Ann Oncol. 2014. PMID: 24928834 Free article. Clinical Trial.
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.
Heidenreich F, Falk B, Baldauf H, Massalski C, Schäfer G, Rücker-Braun E, Altmann H, Sauter J, Solloch UV, Lange V, Stölzel F, Röllig C, Middeke JM, von Bonin M, Thiede C, Schäfer-Eckart K, Müller-Tidow C, Krause SW, Kraus S, Kaufmann M, Hänel M, Serve H, Neubauer A, Bornhäuser M, Schmidt AH, Schetelig J. Heidenreich F, et al. Among authors: hanel m. Blood Adv. 2023 Jul 11;7(13):2994-3004. doi: 10.1182/bloodadvances.2022008514. Blood Adv. 2023. PMID: 36689727 Free PMC article.
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial.
Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, Krause SW, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A, Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C. Ruhnke L, et al. Among authors: hanel m. Haematologica. 2023 Sep 1;108(9):2520-2525. doi: 10.3324/haematol.2022.281636. Haematologica. 2023. PMID: 36779591 Free PMC article. No abstract available.
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR. Hänel M, et al. Among authors: hanel a. Ann Hematol. 2000 Jun;79(6):304-11. doi: 10.1007/s002779900150. Ann Hematol. 2000. PMID: 10901609 Clinical Trial.
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Zwick C, et al. Among authors: hanel m. Ann Hematol. 2008 Sep;87(9):717-26. doi: 10.1007/s00277-008-0500-1. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587579 Clinical Trial.
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Engert A, et al. Among authors: hanel m. J Clin Oncol. 2009 Sep 20;27(27):4548-54. doi: 10.1200/JCO.2008.19.8820. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704068 Clinical Trial.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group. Hanfstein B, et al. Among authors: hanel m. Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26. Leukemia. 2012. PMID: 22446502 Clinical Trial.
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL). Schmitz N, et al. Lancet Oncol. 2012 Dec;13(12):1250-9. doi: 10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16. Lancet Oncol. 2012. PMID: 23168367 Clinical Trial.
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators. Maschmeyer G, et al. Eur J Clin Microbiol Infect Dis. 2013 May;32(5):679-89. doi: 10.1007/s10096-012-1794-4. Epub 2012 Dec 28. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23271674 Clinical Trial.
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G. Schaich M, et al. Among authors: hanel m. J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630210 Clinical Trial.
197 results